

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **May 1, 2023** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the May 1, 2023, updates for complete listings of products available by special authorization, step therapy/special authorization, restricted benefit/special authorization, drug products with changes to criteria for coverage, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross® has confirmed that the shortage for Jamp-Dorzolamide 2% Ophthalmic Solution (DIN 02453347) and Sandoz Dorzolamide 2% Ophthalmic Solution (DIN 02316307) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 15, 2023**. The following grouping was removed from the Critical Supply Product List **April 12, 2023**.

DORZOLAMIDE HCL

2% OPHTHALMIC SOLUTION

00002453347	JAMP DORZOLAMIDE	JPC	\$ 2.1081
00002316307	SANDOZ DORZOLAMIDE	SDZ	\$ 2.1081
00002216205	TRUSOPT	ELV	\$ 4.5465

Alberta Blue Cross has confirmed that the shortage for Act Dextroamphetamine SR 10 mg Sustained-Release Capsule (DIN 02448319) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 19, 2023**. The following grouping was removed from the Critical Supply Product List **April 18, 2023**.

DEXTROAMPHETAMINE SULFATE

10 MG SUSTAINED-RELEASE CAPSULE

00002448319	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.8096
00001924559	DEXEDRINE	PAL	\$ 0.9683

continued next page

continued from previous page

Temporary Benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Hydromorphone 2 mg/mL Injection (DIN 02145901) manufactured by Sandoz Canada Inc., Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) manufactured by Sterimax Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **April 11, 2023**.

As of **April 11, 2023**, all claims for **Hydromorphone HCL 2 mg/mL Injection (DIN 02460602)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php

Due to the unavailability of Teva-Cephalexin 125 25 mg/mL Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 50 mg/mL Oral Suspension (DIN 00342092), Jamp Cephalexin 50 mg/mL Oral Suspension (DIN 02528444) manufactured by Jamp Pharma Corporation will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 9, 2022**.

As of **April 12, 2023**, all claims for **Jamp Cephalexin 50 mg/mL Oral Suspension (DIN 02528444)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Jamp Spironolactone 25 mg Tablet (DIN 02518821) manufactured by Jamp Pharma Corporation, Mint-Spironolactone 25 mg Tablet (DIN 02488140) manufactured by Mint Pharmaceuticals Inc. and Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited, Aldactone 25 mg Tablet (DIN 00028606) manufactured by Pfizer Canada ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Jamp Pharma Corporation, Mint Pharmaceuticals Inc. and Teva Canada Limited have advised Alberta Blue Cross that the shortages for of Jamp Spironolactone 25 mg Tablet (DIN 02518821), Mint-Spironolactone 25 mg Tablet (DIN 02488140) and Teva-Spironolactone 25 mg Tablet (DIN 00613215) have been resolved.

Aldactone 25 mg Tablet (DIN 00028606) will no longer be considered a temporary benefit for the *ADBL* after **May 24, 2023**. The above grouping was removed from the Critical Supply Product List **April 21, 2023**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

